{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:45:18Z","timestamp":1760237118641,"version":"build-2065373602"},"reference-count":150,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T00:00:00Z","timestamp":1582588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Cardiovascular (CV) disease is highly prevalent in the population with chronic kidney disease (CKD), where the risk of CV death in early stages far exceeds the risk of progression to dialysis. The presence of chronic kidney disease-mineral and bone disorder (CKD-MBD) has shown a strong correlation with CV events and mortality. As a non-atheromatous process, it could be partially explained why standard CV disease-modifying drugs do not provide such an impact on CV mortality in CKD as observed in the general population. We summarize the potential association of CV comorbidities with the older (parathyroid hormone, phosphate) and newer (FGF23, Klotho, sclerostin) CKD-MBD biomarkers.<\/jats:p>","DOI":"10.3390\/toxins12030140","type":"journal-article","created":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T04:18:29Z","timestamp":1582690709000},"page":"140","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Should We Consider the Cardiovascular System While Evaluating CKD-MBD?"],"prefix":"10.3390","volume":"12","author":[{"given":"Merita","family":"Rroji","sequence":"first","affiliation":[{"name":"University Department of Nephrology, Faculty of Medicine, University of Medicine Tirana, Tirana 1001, Albania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3766-0312","authenticated-orcid":false,"given":"Andreja","family":"Figurek","sequence":"additional","affiliation":[{"name":"Institute of Anatomy, University of Zurich, Zurich 8057, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goce","family":"Spasovski","sequence":"additional","affiliation":[{"name":"University Department of Nephrology, Medical Faculty, University of Skopje, Skopje 1000, North Macedonia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,2,25]]},"reference":[{"key":"ref_1","unstructured":"(2013). Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Available online: www.usrds.org\/atlas."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.disamonth.2015.07.005","article-title":"Cardiovascular disease and chronic kidney disease","volume":"61","author":"Gargiulo","year":"2015","journal-title":"Dis Mon."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3389\/fmed.2018.00206","article-title":"Uremic Cardiomyopathy: A New Piece in the Chronic Kidney Disease-Mineral and Bone Disorder Puzzle","volume":"5","year":"2018","journal-title":"Front. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1525-139X.2008.00457.x","article-title":"Cardiac problems in the dialysis patient: Beyond coronary disease","volume":"21","author":"Remppis","year":"2008","journal-title":"Semin. Dial."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000435838","article-title":"Left Ventricular Hypertrophy in Chronic Kidney Disease Patients: From Pathophysiology to Treatment","volume":"5","author":"Gorini","year":"2015","journal-title":"Cardio Renal. Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Wang, X., and Shapiro, J.I. (2019). Evolving concepts in the pathogenesis of uraemic cardiomyopathy. Nat. Rev. Nephrol.","DOI":"10.1038\/s41581-018-0101-8"},{"key":"ref_7","first-page":"303","article-title":"Pathophysiology of the Chronic Kidney Disease\u2014Mineral Bone Disorder (CKD-MBD)","volume":"24","author":"Hruska","year":"2015","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"D\u2019Marco, L., Bellasi, A., and Raggi, P. (2015). Cardiovascular biomarkers in chronic kidney disease: State of current research and clinical applicability. Dis. Markers.","DOI":"10.1155\/2015\/586569"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1681\/ASN.V961018","article-title":"Myocyte\/capillary mismatch in the heart of uremic patients","volume":"9","author":"Amann","year":"1998","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1586\/14779072.2014.879040","article-title":"Is uremic cardiomyopathy a direct consequence of chronic kidney disease?","volume":"12","author":"Chinnappa","year":"2014","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijcard.2017.01.015","article-title":"Cardiovascular impact in patients undergoing maintenance hemodialysis: Clinical management considerations","volume":"232","author":"Chirakarnjanakorn","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/MNH.0000000000000231","article-title":"The Role of FGF23 and Klotho in Uremic Cardiomyopathy","volume":"25","author":"Grabner","year":"2016","journal-title":"Curr. Opin. Nephrol. Hypertens"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1525-139X.2008.00454.x","article-title":"Hypertrophy and fibrosis in the cardiomyo pathy of uremia\u2014Beyond coronary heart disease","volume":"21","author":"Gross","year":"2008","journal-title":"Semin. Dial."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/ki.2009.35","article-title":"Left ventricular hypertrophy in renal disease: Beyond preload and afterload","volume":"75","author":"Ritz","year":"2009","journal-title":"Kidney Int."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Fedecostante, M., Spannella, F., Cola, G., Espinosa, E., Dess\u00ec-Fulgheri, P., and Sarzani, R. (2014). Chronic kidney disease is characterized by \u201cdouble trouble\u201d higher pulse pressure plus night-time systolic blood pressure and more severe cardiac damage. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0086155"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.18632\/aging.102046","article-title":"The interplay between mineral metabolism, vascular calcification and inflammation in Chronic Kidney Disease (CKD): Challenging old concepts with new facts","volume":"11","author":"Viegas","year":"2019","journal-title":"Aging"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1161\/ATVBAHA.119.312705","article-title":"Atherosclerosis in Chronic Kidney Disease: More, Less, or Just Different?","volume":"39","author":"Valdivielso","year":"2019","journal-title":"Arterioscler Thromb. Vasc. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/chf.12030","article-title":"Uremic Cardiomyopathy: An Underdiagnosed Disease","volume":"19","author":"Alhaj","year":"2013","journal-title":"Congest. Heart Fail."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/ki.1983.169","article-title":"Cardiovascular changes in chronic hemodialysis patients","volume":"24","author":"Ikram","year":"1983","journal-title":"Kidney Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/ndt\/5.1.39","article-title":"Diffuse intermyocardiocytic fibrosis in uraemic patients","volume":"5","author":"Mall","year":"1990","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/ki.1988.71","article-title":"Myocardial interstitial fibrosis in experimental uremia--implications for cardiac compliance","volume":"33","author":"Mall","year":"1988","journal-title":"Kidney Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.amjcard.2017.11.041","article-title":"Diffuse Myocardial Interstitial Fibrosis and Dysfunction in Early Chronic Kidney Disease","volume":"121","author":"Hayer","year":"2018","journal-title":"Am. J. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.0894-0959.2004.17331.x","article-title":"Cardiac consequences of hypertension in hemodialysis patients","volume":"17","author":"Zoccali","year":"2004","journal-title":"Semin. Dial."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000413122","article-title":"The epidemiology of coronary artery disease in patients on maintenance hemodialysis: Implications for management","volume":"52","author":"Rostand","year":"1986","journal-title":"Contrib. Nephrol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Mohandas, R., Segal, M.S., Huo, T., Handberg, E.M., Petersen, J.W., Johnson, B.D., and Pepine, C.J. (2015). Renal Function and Coronary Microvascular Dysfunction in Women with Symptoms\/Signs of Ischemia. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0125374"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/ndt\/15.2.218","article-title":"Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure","volume":"15","author":"Schwarz","year":"2000","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2215\/CJN.03600414","article-title":"Utility of traditional circulating and imaging-based cardiac biomarkers in patients with predialysis CKD","volume":"10","author":"Colbert","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/ndt\/gfv081","article-title":"Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: Potential partners in vascular calcifications","volume":"30","author":"Morena","year":"2015","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"756","DOI":"10.3945\/ajcn.114.085167","article-title":"Serum magnesium, phosphorus, and calcium are associated with risk of incident heart failure: The Atherosclerosis Risk in Communities (ARIC) Study","volume":"100","author":"Lutsey","year":"2014","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S2213-8587(14)70059-2","article-title":"CKD-MBD Working Group of ERA-EDTA. Bone: A new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders","volume":"2","author":"Vervloet","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Vervloet, M. (2019). Modifying Phosphate Toxicity in Chronic Kidney Disease. Toxins, 11.","DOI":"10.3390\/toxins11090522"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-physiol-030212-183727","article-title":"Fibroblast growth factor 23 and Klotho: Physiology and pathophysiology of an endocrine network of mineral metabolism","volume":"75","author":"Hu","year":"2013","journal-title":"Annu. Rev. Physiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1161\/01.RES.87.7.e10","article-title":"Phosphate regulation of vascular smooth muscle cell calcification","volume":"87","author":"Jono","year":"2000","journal-title":"Circ. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1152\/ajprenal.00163.2014","article-title":"A current understanding of vascular calcification in CKD","volume":"307","author":"Paloian","year":"2014","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/ki.2008.644","article-title":"The emerging role of phosphate in vascular calcification","volume":"75","author":"Giachelli","year":"2009","journal-title":"Kidney Int."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000346784","article-title":"Phosphate Toxicity and Vascular Mineralization. Phosphate and Vitamin D in Chronic Kidney Disease","volume":"180","author":"Razzaque","year":"2013","journal-title":"Contrib. Nephrol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/1744-9987.12030","article-title":"Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients","volume":"17","author":"Taniguchi","year":"2013","journal-title":"Ther. Apher. Dial."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s11255-013-0438-7","article-title":"Is residual renal function and better phosphate control in peritoneal dialysis an answer for the lower prevalence of valve calcification compared to hemodialysis patients?","volume":"46","author":"Rroji","year":"2014","journal-title":"Int. Urol. Nephrol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10157-016-1363-8","article-title":"Mineral metabolism and cardiovascular disease in CKD","volume":"21","author":"Fujii","year":"2017","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Peng, A., Wu, T., Zeng, C., Rakheja, D., Zhu, J., Ye, T., Hutcheson, J., Vaziri, N.D., Liu, Z., and Mohan, C. (2011). Adverse effects of simulated hyper- and hypo-phosphatemia on endothelial cell function and viability. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0023268"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1152\/ajprenal.00003.2008","article-title":"Increased inorganic phosphate induces human endothelial cell apoptosis in vitro","volume":"294","author":"Hausberg","year":"2008","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/ki.2012.300","article-title":"High phosphate directly affects endothelial function by downregulating annexin II","volume":"83","author":"Stock","year":"2013","journal-title":"Kidney Int."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S0272-6386(03)00906-5","article-title":"Circulating endothelial cells as potential markers of the state of the endothelium in hemodialysis patients","volume":"42","author":"Koc","year":"2003","journal-title":"Am. J. Kidney Dis."},{"key":"ref_44","first-page":"1","article-title":"Calciprotein particle (CPP): A true culprit of phosphorus woes?","volume":"34","year":"2014","journal-title":"Nefrologia"},{"key":"ref_45","first-page":"210","article-title":"Calciprotein particle contributes to the synthesis and secretion of fibroblast growth factor 23 induced by dietary phosphate intake","volume":"28","author":"Akiyama","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/ATVBAHA.117.310578","article-title":"Chronic Kidney Disease Circulating Calciprotein Particles and Extracellular Vesicles Promote Vascular Calcification: A Role for GRP (Gla-Rich Protein)","volume":"38","author":"Viegas","year":"2018","journal-title":"Arterioscler Thromb. Vasc. Biol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Akiyama, K., Kimura, T., and Shiizaki, K. (2018). Biological and Clinical Effects of Calciprotein Particles on Chronic Kidney Disease-Mineral and Bone Disorder. Int. J. Endocrinol.","DOI":"10.1155\/2018\/5282389"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Ciceri, P., Falleni, M., Tosi, D., Martinelli, C., Cannizzo, S., Bulfamante, G., Block, G.A., Marchetti, G., and Cozzolino, M. (2019). Therapeutic Effect of Iron Citrate in Blocking Calcium Deposition in High Pi-Calcified VSMC: Role of Autophagy and Apoptosis. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20235925"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MNH.0000000000000503","article-title":"Phosphate, the forgotten mineral in hypertension","volume":"28","author":"Masaki","year":"2019","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1046\/j.1523-1755.2003.00864.x","article-title":"Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia","volume":"63","author":"Amann","year":"2003","journal-title":"Kidney Int."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1681\/ASN.2014050465","article-title":"Klotho and phosphate are modulators of pathologic uremic cardiac remodeling","volume":"26","author":"Hu","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.12659\/MSM.890909","article-title":"Elevated Cardiac Markers in Chronic Kidney Disease as a Consequence of Hyperphosphatemia-Induced Cardiac Myocyte Injury","volume":"20","author":"Wang","year":"2014","journal-title":"Med. Sci. Monit."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1093\/ndt\/gfn613","article-title":"Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease","volume":"24","author":"Covic","year":"2009","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.metabol.2013.08.016","article-title":"Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease","volume":"63","author":"Tomaschitz","year":"2014","journal-title":"Metabolism"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1172\/JCI110137","article-title":"Effect of parathyroid-hormone on rat heart cells","volume":"67","author":"Bogin","year":"1981","journal-title":"J. Clin. Investig."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1093\/ndt\/gfs050","article-title":"FGF23 and PTH\u2014Double agents at the heart of CKD","volume":"27","author":"Silver","year":"2012","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1111\/j.1523-1755.2004.66013.x","article-title":"Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure","volume":"66","author":"Neves","year":"2004","journal-title":"Kidney Int."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/cvr\/cvs092","article-title":"Aldosterone and parathyroid hormone: A precarious couple for cardiovascular disease","volume":"94","author":"Tomaschitz","year":"2012","journal-title":"Cardiovasc. Res."},{"key":"ref_59","first-page":"1739","article-title":"Trophic effects of catecholamines and parathyroid hormone on adult ventricular cardiomyocytes","volume":"263","author":"Schluter","year":"1992","journal-title":"Am. J. Physiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/ndt\/gfr447","article-title":"Parathyroid hormone and phosphorus overload in uremia: Impact on cardiovascular system","volume":"27","author":"Koike","year":"2012","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/CRD.0000000000000250","article-title":"Parathyroid Hormone and Cardiac Electrophysiology: A Review","volume":"27","author":"Palmeri","year":"2019","journal-title":"Cardiol. Rev."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.regpep.2011.06.002","article-title":"PTH-receptors regulate norepinephrine release in human heart and kidney","volume":"171","author":"Potthoff","year":"2011","journal-title":"Regul. Pept."},{"key":"ref_63","first-page":"112","article-title":"Effect of parathyroidectomy on left-ventricular function in haemodialysis patients","volume":"1","author":"Fauchet","year":"1980","journal-title":"Lancet"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/ki.1987.94","article-title":"Uremic cardiomyopathy: An inadequate left ventricular hypertrophy","volume":"31","author":"London","year":"1987","journal-title":"Kidney Int."},{"key":"ref_65","first-page":"246","article-title":"Pathogenetic aspects of uremic cardiomyopathy","volume":"15","author":"Coratelli","year":"1989","journal-title":"Miner Electrolyte Metab."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0272-6386(12)80090-4","article-title":"Parathyroid hormone and myocardial performance in dialysis patients","volume":"18","author":"Fellner","year":"1991","journal-title":"Am. J. Kidney Dis."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Evolve Trial Investigators, Chertow, G.M., Block, G.A., Correa-Rotter, R., Dr\u00fceke, T.B., Floege, J., Goodman, W.G., Herzog, C.A., Kubo, Y., and London, G.M. (2012). Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N. Engl. J. Med., 367, 2482\u20132494.","DOI":"10.1056\/NEJMoa1205624"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1097\/01.hjh.0000179764.40701.36","article-title":"Serum parathyroid hormone as a predictor of increase in systolic blood pressure in men","volume":"23","author":"Jorde","year":"2005","journal-title":"J. Hypertens."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2459\/JCM.0000000000000614","article-title":"Vitamin D, parathyroid hormone and cardiovascular risk: The good, the bad and the ugly","volume":"19","author":"Pascale","year":"2018","journal-title":"J. Cardiovasc. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"269","DOI":"10.18632\/aging.100740","article-title":"Coronary artery calcifications predict long term cardiovascular events in nondiabetic Caucasian hemodialysis patients","volume":"7","author":"Noce","year":"2015","journal-title":"Aging"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"SHARP Investigators: The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): A randomized placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/ndt\/gfv111","article-title":"Vascular calcification in chronic kidney disease: An update","volume":"31","author":"Schlieper","year":"2016","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1681\/ASN.2005080834","article-title":"Endothelial dysfunction contributes to renal function associated cardiovascular mortality in a population with mild renal insufficiency: The Hoorn study","volume":"17","author":"Stam","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S2213-8587(14)70113-5","article-title":"Association of vitamin D status with arterial blood pressure and hypertension risk: A mendelian randomisation study","volume":"2","author":"Vimaleswaran","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/clc.22473","article-title":"Vitamin D supplementation in the treatment of chronic heart failure: A meta-analysis of randomized controlled trials","volume":"39","author":"Jiang","year":"2016","journal-title":"Clin. Cardiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/ckj\/sfu122","article-title":"Effect of oral vitamin D analogs on mortality and cardiovascular outcomes among adults with chronic kidney disease: A meta-analysis","volume":"8","author":"Mann","year":"2015","journal-title":"Clin. Kidney J."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jsbmb.2018.01.001","article-title":"Vascular function and cholecalciferol supplementation in CKD: A self-controlled case series","volume":"180","author":"Kumar","year":"2018","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Chitalia, N., Ismail, T., Tooth, L., Boa, F., Hampson, G., Goldsmith, D., Kaski, J.C., and Banerjee, D. (2014). Impact of vitamin D supplementation on arterial vasomotion, stiffness and endothelial biomarkers in chronic kidney disease patients. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0091363"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1002\/ejhf.821","article-title":"Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction","volume":"19","author":"Szummer","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Lundwall, K., Jacobson, S.H., J\u00f6rneskog, G., and Spaak, J. (2018). Treating endothelial dysfunction with vitamin D in chronic kidney disease: A metaanalysis. BMC Nephrol., 19.","DOI":"10.1186\/s12882-018-1042-y"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1161\/CIRCULATIONAHA.111.032680","article-title":"Cardiomyocyte-specific deletion of the vitamin D receptor gene results in cardiac hypertrophy","volume":"124","author":"Chen","year":"2011","journal-title":"Circulation"},{"key":"ref_82","first-page":"675","article-title":"Involvement of vitamin D3 with cardiovascular function. II. Direct and indirect effects","volume":"253","author":"Weishaar","year":"1987","journal-title":"Am. J. Physiol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1172\/JCI113010","article-title":"Vitamin D3 and cardiovascular function in rats","volume":"79","author":"Weishaar","year":"1987","journal-title":"J. Clin. Investig."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1172\/JCI118582","article-title":"1.25 (OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes","volume":"97","author":"Wu","year":"1996","journal-title":"J. Clin. Investig."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/cvr\/cvr133","article-title":"Preventing progression of cardiac hypertrophy and development of heart failure by paricalcitol therapy in rats","volume":"91","author":"Bae","year":"2011","journal-title":"Cardiovasc. Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1681\/ASN.2013010103","article-title":"Effect of paricalcitol on left ventricular mass and function in CKD\u2014The OPERA trial","volume":"25","author":"Wang","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1001\/jama.2012.120","article-title":"Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: The PRIMO randomized controlled trial","volume":"307","author":"Thadhani","year":"2012","journal-title":"JAMA"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/ejcn.2017.59","article-title":"Effects of vitamin or its analogues on the mortality of patients with chronic kidney disease: An updated systematic review and meta-analysis","volume":"71","author":"Lu","year":"2017","journal-title":"Eur. J. Clin. Nutr."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1152\/ajprenal.00474.2004","article-title":"Vitamin D receptor-intependent FGF23 actions in regulating phosphate and vitamin D metabolism","volume":"289","author":"Shimada","year":"2005","journal-title":"Am. J. Physiolol. Ren. Physiol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1681\/ASN.2012080865","article-title":"Loss of Klotho contributes to kidney injury by derepression of Wnt\/\u03b2-catenin signaling","volume":"24","author":"Zhou","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Lindberg, K., Olauson, H., Amin, R., Ponnusamy, A., Goetz, R., Taylor, R.F., Mohammadi, M., Canfield, A., Kublickiene, K., and Larsson, T.E. (2013). Arterial Klotho expression and FGF23 effects on vascular calcification and function. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0060658"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1038\/ncomms2240","article-title":"Cardioprotection by Klotho through downregulation of TRPC6 channels in the mouse heart","volume":"3","author":"Xie","year":"2012","journal-title":"Nat. Commun."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ki.2011.47","article-title":"Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease","volume":"79","author":"Isakova","year":"2011","journal-title":"Kidney Int."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/1744-9987.12592","article-title":"FGF23 level and intima-media thickness are elevated from early stages of chronic kidney disease","volume":"22","author":"Figurek","year":"2018","journal-title":"Ther. Apher. Dial."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000496220","article-title":"Meta-Analysis of the association between fibroblast growth factor 23 and mortality and cardiovascular events in hemodialysis patients","volume":"47","author":"Gao","year":"2019","journal-title":"Blood Purif."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1681\/ASN.2017070772","article-title":"Longitudinal FGF23 trajectories and mortality in patients with CKD","volume":"29","author":"Isakova","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Silva, A.P., Mendes, F., Carias, E., Goncalves, R.B., Fragoso, A., Dias, C., Tavares, N., Cafe, H.M., Santos, N., and Rato, F. (2019). Plasmatic Klotho and FGF23 levels as biomarkers of CKD-associated cardiac disease in type 2 diabetic patients. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20071536"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Dai, B., David, V., Martin, A., Huang, J., Li, H., Jiao, Y., Gu, W., and Quarles, L.D. (2012). A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0044161"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1093\/ndt\/gfy006","article-title":"Fibroblast growth factor 23 is induced by an activated renin-angiotensin-aldosterone system in cardiac myocytes and promotes the pro-fibrotic crosstalk between cardiac myocytes and fibroblasts","volume":"33","author":"Kirchhoff","year":"2018","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1096\/fj.201700667R","article-title":"Inhibition of fibroblast growth factor 23 (FGF23) signaling rescues renal anemia","volume":"32","author":"Agoro","year":"2018","journal-title":"FASEB J."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_102","first-page":"66","article-title":"FGF23 induced left ventricular hypertrophy mediated by FGFR4 signaling in the myocardium is attenuated by soluble Klotho in mice","volume":"21","author":"Han","year":"2019","journal-title":"J. Mol. Cell Cardiol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.kint.2018.02.018","article-title":"Cardiac hypertrophy elevates serum levels of fibroblast growth factor 23","volume":"94","author":"Matsui","year":"2018","journal-title":"Kidney Int."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.2337\/dc19-0528","article-title":"Fibroblast growth factor 23 and mortality in patients with type 2 diabetes and normal or mildly impaired kidney function","volume":"42","author":"Yeung","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.nefro.2018.10.007","article-title":"FGF23 in hemodialysis patients is associated with left ventricular hypertrophy and reduced ejection fraction","volume":"39","author":"Nielsen","year":"2019","journal-title":"Nefrologia"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ijcard.2015.04.074","article-title":"Comparison of fibroblast growth factor 23, soluble ST2 and Galectin-3 for prognostication of cardiovascular death in heart failure patients","volume":"189","author":"Gruson","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1038\/s41598-017-02068-6","article-title":"FGF23\/FGFR4-mediated left ventricular hypertrophy is reversible","volume":"16","author":"Grabner","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1093\/ndt\/gfw454","article-title":"Vitamin D treatment attenuates cardiac FGF23\/FGFR4 signaling and hypertrophy in uremic rats","volume":"32","author":"Grabner","year":"2017","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.kint.2019.07.026","article-title":"Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease","volume":"96","author":"Francis","year":"2019","journal-title":"Kidney Int."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bone.2017.01.017","article-title":"Potential application of klotho in human chronic kidney disease","volume":"100","author":"Neyra","year":"2017","journal-title":"Bone"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000353593","article-title":"The role of fibroblast growth factor-23 in cardiorenal syndrome","volume":"123","author":"Kovesdy","year":"2013","journal-title":"Nephron Clin. Pract."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1681\/ASN.2014040325","article-title":"Soluble Klotho Protects against Uremic Cardiomyopathy Independently of Fibroblast Growth Factor 23 and Phosphate","volume":"26","author":"Xie","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.yjmcc.2019.09.004","article-title":"The axis of local cardiac endogenous Klotho-TGF-\u03b21-Wnt signaling mediates cardiac fibrosis in human","volume":"136","author":"Liu","year":"2019","journal-title":"J. Mol. Cell Cardiol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1159\/000362251","article-title":"Left ventricular mass progression despite stable blood pressure and kidney function in stage 3 chronic kidney disease","volume":"39","author":"Seifert","year":"2014","journal-title":"Am. J. Nephrol."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Memmos, E., Sarafidis, P., Pateinakis, P., Tsiantoulas, A., Faitatzidou, D., Giamalis, P., Vasilikos, V., and Papagianni, A. (2019). Soluble Klotho is associated with mortality and cardiovascular events in hemodialysis. BMC Nephrol., 11.","DOI":"10.1186\/s12882-019-1391-1"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.atherosclerosis.2015.08.017","article-title":"Soluble klotho and mortality: The Ludwigshafen Risk and Cardiovascular Health Study","volume":"242","author":"Brandenburg","year":"2015","journal-title":"Atherosclerosis"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Kim, H.J., Kang, E., Oh, Y.K., Kim, Y.H., Han, S.H., Yoo, T.H., Chae, D.W., Lee, J., Ahn, C., and Oh, K.H. (2018). The association between soluble klotho and cardiovascular parameters in chronic kidney disease: Results from the KNOW-CKD study. BMC Nephrol., 5.","DOI":"10.1186\/s12882-018-0851-3"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1007\/s00018-019-03241-y","article-title":"\u03b1Klotho-FGF23 interactions and their role in kidney disease: A molecular insight","volume":"76","author":"Smith","year":"2019","journal-title":"Cell Mol. Life Sci."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00109-017-1527-3","article-title":"Klotho suppresses high phosphate-induced osteogenic responses in human aortic valve interstitial cells through inhibition of Sox9","volume":"95","author":"Li","year":"2017","journal-title":"J. Mol. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.kint.2016.10.034","article-title":"Recombinant \u03b1-Klotho may be prophylactic and therapeutic for acute to chronic kidney disease progression and uremic cardiomyopathy","volume":"91","author":"Hu","year":"2017","journal-title":"Kidney Int."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2215\/CJN.07870713","article-title":"Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2-4","volume":"6","author":"Seiler","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000452880","article-title":"Klotho\/FGF23 Axis in Chronic Kidney Disease and Cardiovascular Disease","volume":"3","author":"Lu","year":"2017","journal-title":"Kidney Dis."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1093\/emboj\/cdg599","article-title":"Osteocyte control of bone formation via sclerostin, a novel BMP antagonist","volume":"22","author":"Winkler","year":"2003","journal-title":"EMBO J."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1136\/annrheumdis-2013-203345","article-title":"Sclerostin inhibition reverses systemic periarticular and local bone loss in arthritis","volume":"72","author":"Chen","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_125","first-page":"319","article-title":"SOST\/sclerostin, an osteocyte-derived negative regulator of bone formation","volume":"6","author":"Papapoulos","year":"2005","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1177\/0022034509338340","article-title":"Sclerostin in mineralised matrices and van Buchem disease","volume":"88","author":"Bronckers","year":"2009","journal-title":"J. Dent. Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1074\/jbc.M400524200","article-title":"Sclerostin inhibition of Wnt-3a-induced C3H10T1\/2 cell differentiation is indirect and mediated by bone morphogenetic proteins","volume":"280","author":"Winkler","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1086\/318811","article-title":"Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot containing protein","volume":"68","author":"Brunkow","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/hmg\/10.5.537","article-title":"Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)","volume":"10","author":"Balemans","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/elps.1150180333","article-title":"A comparison of selected mRNA and protein abundances in human liver","volume":"18","author":"Anderson","year":"1997","journal-title":"Electrophoresis"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1007\/s11255-018-1935-5","article-title":"Is serum sclerostin a marker of atherosclerosis in patients with chronic kidney disease-mineral and bone disorder?","volume":"50","author":"Figurek","year":"2018","journal-title":"Int. Urol. Nephol."},{"key":"ref_132","first-page":"317","article-title":"Sclerostin as a potential novel biomarker for aortic valve calcification: An in-vivo and ex-vivo study","volume":"22","author":"Koos","year":"2013","journal-title":"J. Heart Valve Dis."},{"key":"ref_133","first-page":"8822","article-title":"Serum sclerostin as a potential novel biomarker for heart valve calcification in patients with chronic kidney disease","volume":"22","author":"Ji","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.nephro.2014.04.002","article-title":"Uremic toxicity and sclerostin in chronic kidney disease patients","volume":"10","author":"Desjardins","year":"2014","journal-title":"Nephrol. Ther."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1159\/000501205","article-title":"Increased Sclerostin, but Not Dickkopf-1 Protein, Is Associated with Elevated Pulse Wave Velocity in Hemodialysis Subjects","volume":"44","author":"Stavrinou","year":"2019","journal-title":"Kidney Blood Press. Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.nefro.2015.07.006","article-title":"Serum sclerostin levels, arteriovenous fistula calcification and 2-years all-cause mortality in prevalent hemodialysis patients","volume":"36","author":"Kirkpantur","year":"2016","journal-title":"Nefrologia"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"547","DOI":"10.33549\/physiolres.934034","article-title":"Sclerostin levels predict cardiovascular mortality in long-term hemodialysis patients: A prospective observational cohort study","volume":"29","author":"Kalousova","year":"2019","journal-title":"Physiol. Res."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Liao, R., Wang, L., Li, J., Sun, S., Xiong, Y., Li, Y., Han, M., Jiang, H., Anil, M., and Su, B. (2019). Vascular calcification is associated with Wnt-signaling pathway and blood pressure variability in chronic kidney disease rats. Nephrology.","DOI":"10.1093\/ndt\/gfz101.SaO049"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5414\/CN109333","article-title":"Sclerostin is not associated with cardiovascular event or fracture in kidney transplantation candidates","volume":"90","author":"Jorgensen","year":"2018","journal-title":"Clin. Nephrol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1007\/s11255-016-1387-8","article-title":"Sclerostin, cardiovascular disease and mortality: A systematic review and meta-analysis","volume":"48","author":"Kanbay","year":"2016","journal-title":"Int. Urol. Nephrol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"E1854","DOI":"10.1210\/jc.2014-2042","article-title":"Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients","volume":"99","author":"Kanbay","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/ndt\/gfu301","article-title":"NECOSAD Study Group. High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: Results from the NECOSAD study","volume":"30","author":"Drechsler","year":"2015","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/1759720X17726744","article-title":"Sclerostin antibodies in osteoporosis: Latest evidence and therapeutic potential","volume":"9","author":"McClung","year":"2017","journal-title":"Ther. Adv. Musculoskelet Dis."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"115121","DOI":"10.1016\/j.bone.2019.115121","article-title":"Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta-analysis","volume":"130","author":"Lv","year":"2020","journal-title":"Bone"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.molmed.2009.07.001","article-title":"Vascular calcification and bone disease: The calcification paradox","volume":"15","author":"Persy","year":"2009","journal-title":"Trends Mol. Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1161\/01.RES.0000149165.99974.12","article-title":"Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin","volume":"95","year":"2004","journal-title":"Circ. Res."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","article-title":"Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification","volume":"12","author":"Bucay","year":"1998","journal-title":"Genes. Dev."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1084\/jem.192.4.463","article-title":"Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis","volume":"192","author":"Min","year":"2000","journal-title":"J. Exp. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1161\/01.ATV.0000059406.92165.31","article-title":"Osteo\/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler","volume":"23","author":"Tyson","year":"2003","journal-title":"Thromb. Vasc. Biol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2215\/CJN.11191111","article-title":"Osteoprotegerin\/RANKL axis and progression of coronary artery calcification in hemodialysis patients","volume":"7","author":"Ozkok","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/12\/3\/140\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:01:31Z","timestamp":1760173291000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/12\/3\/140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,25]]},"references-count":150,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3]]}},"alternative-id":["toxins12030140"],"URL":"https:\/\/doi.org\/10.3390\/toxins12030140","relation":{},"ISSN":["2072-6651"],"issn-type":[{"type":"electronic","value":"2072-6651"}],"subject":[],"published":{"date-parts":[[2020,2,25]]}}}